BJH - volume 7, issue 1, february 2016
T. Feys MBA, MSc
Major therapeutic progress has been accomplished in chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPN) over the past 40 years. Therapeutic progress happened through better understanding of disease pathophysiologiy and rational development of targeted agents, like imatinib mesylate in CML. This report will discuss the key studies related to CML or MDS, presented during the 2015 annual ASH meeting of the American Society of Hematology (ASH).
(BELG J HEMATOL 2016; 7(1):9–13)
Read moreBJH - volume 7, issue 1, february 2016
T. Feys MBA, MSc
At the 2015 annual meeting of the American Society of Hemtology (ASH), potentially practice-changing novelties were published, which reform our way of thinking about sickle cell disease. Three highlighted studies were mentioned, two of these present promising new insights for managing the disease in children, the third demonstrates a new oral therapy.
(BELG J HEMATOL 2016; 7(1): 53–4)
Read moreBJH - volume 7, issue 1, february 2016
T. Feys MBA, MSc
(BELG J HEMATOL; 7(1):55–8)
Read moreBJH - volume 7, issue 1, february 2016
T. Feys MBA, MSc
Overview of Belgian reimbursement news
(BELG J HEMATOL 2016; 7(1):59)
Read moreBJH - volume 6, issue 5, december 2015
T. Feys MBA, MSc
Overview of Belgian reimbursement news
(Belg J Hematol 2015;6(5):225)
Read moreBJH - volume 6, issue 3, september 2015
T. Feys MBA, MSc
(BELG J HEMATOL 2015;6(3):93–5)
Read moreBJH - volume 4, issue 1, march 2013
T. Feys MBA, MSc
From the 8th till the 11th of December 2012, Atlanta, Georgia formed the background for the 54th annual meeting of the American Society of Hematology (ASH). With more than 20,000 attendees from 108 countries, the ASH annual meeting again proved to be without question the premier hematology meeting in the world. This report does not aim to summarise the entire meeting, but simply lists the key messages from this years’ meeting. For more elaborate information on the meeting, and a complete overview of the presented abstracts we would like to refer to the ASH website, www.hematology.org.
(BELG J HEMATOL 2013;1:39–42)
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.